10-Q: Acutus Medical Reports Q2 2024 Results, Revenue Increases Significantly Following Strategic Shift

Acutus Medical's Q2 2024 results show a significant increase in revenue due to its strategic shift to manufacturing for Medtronic, despite continued losses.

Summary

• Acutus Medical reported a net loss of $914,000 for the second quarter of 2024, compared to a net loss of $18.3 million for the same period in 2023.
• The company's revenue increased to $4.1 million in Q2 2024, up from $1.5 million in Q2 2023, primarily due to increased sales of left-heart access products to Medtronic.
• The company's strategic restructuring, initiated in late 2023, involved winding down its mapping and ablation businesses to focus on manufacturing for Medtronic.
• Acutus Medical's cash, cash equivalents, restricted cash, and marketable securities totaled $13.3 million as of June 30, 2024, down from $29.4 million at the end of 2023.
• The company's accumulated deficit was $602.5 million as of June 30, 2024, compared to $600.0 million at the end of 2023.
• The company has recognized $24.1 million of the estimated $21.0 million to $32.0 million of pre-tax restructuring and exit-related charges.
• Acutus Medical's common stock was delisted from Nasdaq on May 26, 2024, and now trades on the OTC Pink Market under the symbol AFIB.

Sentiment

Score: 5

Explanation: The document shows a mixed sentiment. While there are positive signs of revenue growth and improved margins due to the strategic shift, the company is still operating at a loss, has reduced cash reserves, and faces significant risks. The delisting from Nasdaq is a major negative factor.

Positives

• The company's revenue has significantly increased due to its focus on manufacturing for Medtronic.
• Gross margins have improved, indicating better cost management and manufacturing efficiencies.
• Net losses have decreased substantially compared to the previous year, showing progress in financial performance.
• The company has secured contingent payments based on Medtronic's sales, providing a potential revenue stream.
• The strategic restructuring is substantially complete, which should lead to reduced operating expenses.

Negatives

• The company continues to operate at a loss, despite improvements.
• Cash reserves have decreased significantly, raising concerns about long-term financial stability.
• The company's stock was delisted from Nasdaq, which may negatively impact investor confidence.
• The company is heavily reliant on Medtronic for revenue, creating a significant dependency risk.
• The company has incurred substantial restructuring costs, impacting profitability.

Risks

• The company's reliance on Medtronic for revenue makes it vulnerable to changes in Medtronic's business or demand for the products.
• Manufacturing or supplier disruptions could lead to product shortages and impact revenue.
• The company may not achieve the anticipated cost savings or benefits from the restructuring.
• The company faces intense competition in the medical device industry.
• Global supply chain disruptions could negatively affect the company's costs and operations.
• The company is involved in ongoing legal proceedings, including an arbitration with Biotronik, which could result in significant costs and liabilities.

Future Outlook

Management believes the company's current cash, cash equivalents, and marketable securities are sufficient to fund operations for at least the next 12 months from the date of this filing. The company will continue to focus on manufacturing and distributing products for Medtronic and potentially earning associated earnout payments.

Management Comments

• Management believes the company's current cash, cash equivalents and marketable securities are sufficient to fund operations for at least the next 12 months from the date of this filing.
• The Restructuring is intended to reduce the company's operating expenses and optimize its cash resources.
• Management continues to review cost improvement opportunities and pathways to reduce expenses and cash burn.

Industry Context

The company's strategic shift reflects a broader trend in the medical device industry where companies are focusing on core competencies and strategic partnerships. The move to become a manufacturing partner for a larger company like Medtronic is a common strategy for smaller firms to leverage their technology and expertise while reducing financial risk.

Comparison to Industry Standards

• Acutus Medical's revenue growth of 172% in Q2 2024 is significantly higher than the average growth rate for medical device companies, which typically ranges from 5% to 15% annually. However, this growth is from a low base and is largely due to the Medtronic partnership.
• The company's negative gross margin of 8% in Q2 2024 is still below industry standards, where gross margins typically range from 50% to 70% for medical device manufacturers. However, the improvement from negative 67% in the prior year is a positive sign.
• Companies like Boston Scientific and Abbott, which are major players in the electrophysiology market, have significantly higher revenue and profitability, highlighting the challenges Acutus Medical faces in competing directly.
• The delisting from Nasdaq and move to the OTC Pink Market is a significant deviation from industry norms for publicly traded medical device companies, which typically maintain listings on major exchanges to attract investors.
• The company's reliance on a single customer, Medtronic, is a significant risk compared to companies with diversified customer bases. For example, companies like Stryker and Medtronic themselves have a wide range of customers and products.

Legal Proceedings

• The company was involved in two putative securities class action lawsuits, which were dismissed by the court, and the plaintiff voluntarily dismissed the appeal.
• The company is involved in an arbitration with Biotronik, alleging breach of contract, with Biotronik seeking $38 million in damages.

Related Party Transactions

• The company has a credit agreement with related parties Deerfield Private Design Fund III, L.P. and Deerfield Partners, L.P.
• The company issued warrants to Deerfield in connection with the credit agreement.

Stakeholder Impact

• Shareholders have experienced a significant decrease in the value of their investment due to the delisting from Nasdaq.
• Employees have been impacted by the workforce reduction as part of the restructuring.
• The company's customers are now primarily Medtronic, which has shifted the company's focus.
• Suppliers are impacted by the company's shift in manufacturing focus and reduced operations.
• Creditors are exposed to the company's ongoing financial challenges and debt obligations.

Next Steps

• The company will continue to focus on manufacturing and distributing products for Medtronic.
• The company will continue to explore strategic alternatives for its mapping and ablation businesses.
• Management will continue to review cost improvement opportunities and pathways to reduce expenses and cash burn.

Key Dates

Keywords

Acutus Medical, Medtronic, Restructuring, Left-Heart Access, Manufacturing, Revenue, Net Loss, Gross Margin, Delisting, OTC Pink Market, Contingent Consideration, Arbitration, Medical Devices